Miacalcin

Hypercalcemia, Osteoporotic Fractures, Osteoporosis + 5 more
Treatment
20 Active Studies for Miacalcin

What is Miacalcin

Salmon calcitoninThe Generic name of this drug
Treatment SummaryA synthetic nasal spray made up of 32 amino acids.
Miacalcinis the brand name
Miacalcin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Miacalcin
Salmon calcitonin
1986
16

Effectiveness

How Miacalcin Affects PatientsCalcitonin stops the breakdown of bones by osteoclasts and helps build up new bone cells. This increases the overall amount of bone in the body and lowers the amount of calcium in the blood. It also helps the kidneys flush out other ions like phosphate, sodium, magnesium, and potassium, which leads to increased water, sodium, potassium, and chloride secretion in the small intestine.
How Miacalcin works in the bodyCalcitonin helps to increase bone density by binding to receptors found in osteoclasts. This binding activates enzymes that help the body absorb and retain calcium. It also triggers pathways in the body that help increase bone density.

When to interrupt dosage

The suggested dosage of Miacalcin is contingent upon the determined condition, such as Osteoporosis, Postmenopause and Hypercalcemia. The measurement of dosage shifts, in accordance with the technique of delivery (e.g. Injection, solution or Intramuscular; Subcutaneous) as highlighted in the table below.
Condition
Dosage
Administration
Immobilization
, 200.0 [iU], 2200.0 [iU]/mL, 20000.0 [iU]/mL, 200.0 [iU]/mL, 100.0 [iU], 200.0 [USP'U]/mL, 200.0 units/mL, 200.0 units/pump actuation, 100.0 units/mL, 200.0 units/spray
, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Intramuscular; Subcutaneous, Solution, Solution - Intramuscular; Subcutaneous, Liquid, Liquid - Intramuscular; Subcutaneous, Spray - Nasal, Spray, Solution - Nasal, Liquid - Nasal, Liquid - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous
Postmenopause
, 200.0 [iU], 2200.0 [iU]/mL, 20000.0 [iU]/mL, 200.0 [iU]/mL, 100.0 [iU], 200.0 [USP'U]/mL, 200.0 units/mL, 200.0 units/pump actuation, 100.0 units/mL, 200.0 units/spray
, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Intramuscular; Subcutaneous, Solution, Solution - Intramuscular; Subcutaneous, Liquid, Liquid - Intramuscular; Subcutaneous, Spray - Nasal, Spray, Solution - Nasal, Liquid - Nasal, Liquid - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous
Paget’s Disease
, 200.0 [iU], 2200.0 [iU]/mL, 20000.0 [iU]/mL, 200.0 [iU]/mL, 100.0 [iU], 200.0 [USP'U]/mL, 200.0 units/mL, 200.0 units/pump actuation, 100.0 units/mL, 200.0 units/spray
, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Intramuscular; Subcutaneous, Solution, Solution - Intramuscular; Subcutaneous, Liquid, Liquid - Intramuscular; Subcutaneous, Spray - Nasal, Spray, Solution - Nasal, Liquid - Nasal, Liquid - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous
Hypercalcemia
, 200.0 [iU], 2200.0 [iU]/mL, 20000.0 [iU]/mL, 200.0 [iU]/mL, 100.0 [iU], 200.0 [USP'U]/mL, 200.0 units/mL, 200.0 units/pump actuation, 100.0 units/mL, 200.0 units/spray
, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Intramuscular; Subcutaneous, Solution, Solution - Intramuscular; Subcutaneous, Liquid, Liquid - Intramuscular; Subcutaneous, Spray - Nasal, Spray, Solution - Nasal, Liquid - Nasal, Liquid - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous
Osteoporotic Fractures
, 200.0 [iU], 2200.0 [iU]/mL, 20000.0 [iU]/mL, 200.0 [iU]/mL, 100.0 [iU], 200.0 [USP'U]/mL, 200.0 units/mL, 200.0 units/pump actuation, 100.0 units/mL, 200.0 units/spray
, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Intramuscular; Subcutaneous, Solution, Solution - Intramuscular; Subcutaneous, Liquid, Liquid - Intramuscular; Subcutaneous, Spray - Nasal, Spray, Solution - Nasal, Liquid - Nasal, Liquid - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous
Osteoporosis
, 200.0 [iU], 2200.0 [iU]/mL, 20000.0 [iU]/mL, 200.0 [iU]/mL, 100.0 [iU], 200.0 [USP'U]/mL, 200.0 units/mL, 200.0 units/pump actuation, 100.0 units/mL, 200.0 units/spray
, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Intramuscular; Subcutaneous, Solution, Solution - Intramuscular; Subcutaneous, Liquid, Liquid - Intramuscular; Subcutaneous, Spray - Nasal, Spray, Solution - Nasal, Liquid - Nasal, Liquid - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous
Osteitis Deformans
, 200.0 [iU], 2200.0 [iU]/mL, 20000.0 [iU]/mL, 200.0 [iU]/mL, 100.0 [iU], 200.0 [USP'U]/mL, 200.0 units/mL, 200.0 units/pump actuation, 100.0 units/mL, 200.0 units/spray
, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Intramuscular; Subcutaneous, Solution, Solution - Intramuscular; Subcutaneous, Liquid, Liquid - Intramuscular; Subcutaneous, Spray - Nasal, Spray, Solution - Nasal, Liquid - Nasal, Liquid - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous
Therapeutic procedure
, 200.0 [iU], 2200.0 [iU]/mL, 20000.0 [iU]/mL, 200.0 [iU]/mL, 100.0 [iU], 200.0 [USP'U]/mL, 200.0 units/mL, 200.0 units/pump actuation, 100.0 units/mL, 200.0 units/spray
, Nasal, Spray, metered, Spray, metered - Nasal, Intramuscular, Injection, solution, Injection, solution - Intramuscular, Intramuscular; Subcutaneous, Solution, Solution - Intramuscular; Subcutaneous, Liquid, Liquid - Intramuscular; Subcutaneous, Spray - Nasal, Spray, Solution - Nasal, Liquid - Nasal, Liquid - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Injection, solution - Intramuscular; Subcutaneous

Warnings

There are 20 known major drug interactions with Miacalcin.
Common Miacalcin Drug Interactions
Drug Name
Risk Level
Description
Abacavir
Minor
Salmon calcitonin may decrease the excretion rate of Abacavir which could result in a higher serum level.
Acetaminophen
Minor
Salmon calcitonin may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
Acetohexamide
Minor
The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Salmon calcitonin.
Aclidinium
Minor
Salmon calcitonin may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine
Minor
Salmon calcitonin may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Miacalcin Toxicity & Overdose RiskSalmon calcitonin is not recommended for nursing mothers, as it has been linked to decreased fetal weight in animals. It is important to weigh the pros and cons when administering salmon calcitonin to pregnant women. In addition, salmon calcitonin can cause allergic reactions, including swelling of the tongue or throat, and an increased risk in malignancies. Other side effects include nausea, rhinitis, headaches, and back pain.
image of a doctor in a lab doing drug, clinical research

Miacalcin Novel Uses: Which Conditions Have a Clinical Trial Featuring Miacalcin?

57 active clinical trials are in progress to examine the possibility of using Miacalcin to facilitate Therapeutic procedures, Postmenopausal states and Osteitis Deformans.
Condition
Clinical Trials
Trial Phases
Hypercalcemia
1 Actively Recruiting
Phase 4
Immobilization
0 Actively Recruiting
Paget’s Disease
0 Actively Recruiting
Osteoporotic Fractures
3 Actively Recruiting
Phase 4, Not Applicable
Osteoporosis
27 Actively Recruiting
Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2
Osteitis Deformans
0 Actively Recruiting
Postmenopause
5 Actively Recruiting
Phase 2, Not Applicable
Therapeutic procedure
0 Actively Recruiting

Miacalcin Reviews: What are patients saying about Miacalcin?

5Patient Review
11/14/2007
Miacalcin for Decreased Bone Mass Following Menopause
I've been using Miacalcin for a while now, and it's easy to use but slow-acting. My bone density test showed that I was losing bone mass, so now I take it in combination with Boniva.
5Patient Review
2/28/2008
Miacalcin for Decreased Bone Mass Following Menopause
This medication has increased my bone density, and I've been using it for a while now without any issues.
5Patient Review
6/18/2010
Miacalcin for Decreased Bone Mass Following Menopause
Miacalcin was working great for me, but since my insurance company raised the price beyond what I can afford, I've experienced a significant amount of bone loss.
5Patient Review
6/22/2009
Miacalcin for Decreased Bone Mass Following Menopause
Miacalcin not only improved the results on my spine, but has kept my readings from my hip bone stable for the past three years.
4.7Patient Review
4/4/2009
Miacalcin for Decreased Bone Mass Following Menopause
I had no issues taking this medication, and it didn't come with any unwanted side effects. However, after a year of use my bone density test did not show any improvement.
4Patient Review
10/7/2008
Miacalcin for Decreased Bone Mass Following Menopause
This treatment has been easy to use and I haven't had any negative side effects so far. My next bone scan will give more information.
4Patient Review
9/18/2007
Miacalcin for Decreased Bone Mass Following Menopause
3.7Patient Review
9/29/2009
Miacalcin for Decreased Bone Mass Following Menopause
Easy enough to use - I just put the bottle in the cabinet on whichever side I used it that day, so I know to switch sides tomorrow. The only problem is that I've started losing hair since using this medication and don't know if it's related.
3Patient Review
3/2/2010
Miacalcin for Decreased Bone Mass Following Menopause
I've been using this treatment for four years to help with osteoperosis. While there has been some improvement in my bone mass, it's only been slight. I also experienced a lot of nosebleeds and redness on the top of my nose while using this product. Thankfully, those side effects have gone away since discontinuing use six weeks ago.
3Patient Review
3/16/2010
Miacalcin for Osteoporosis
This treatment really helped me. I'm grateful for modern medicine.
3Patient Review
10/26/2007
Miacalcin for Decreased Bone Mass Following Menopause
I'm optimistic about this treatment.
2.3Patient Review
12/3/2008
Miacalcin for Decreased Bone Mass Following Menopause
I had no problems using this for about a year, but now I sneeze uncontrollably whenever I use it. Additionally, I experienced unexplained back pain that has since gone away after discontinuing use. However, my bone density did improve while taking Miacalcin with Evista, so I'm not happy that I can't use it anymore. There is also a generic Fortical available.
1Patient Review
2/3/2014
Miacalcin for Decreased Bone Mass Following Menopause
I was taking calcitonin salmon for a couple of years before my drug supplier changed and started sending me Miacalin instead. It smells disgustingly, like old garbage. Even with the previous medication I was getting daily headaches and sinus pain. My doctor encouraged me to keep using it but the side effects are not worth it to me.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about miacalcin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Miacalcin made from salmon?

"Miacalcin is a hormone that is found naturally in the thyroid gland. It is used to treat Paget's disease of bone, postmenopausal osteoporosis, or high levels of calcium in the blood (hypercalcemia)."

Answered by AI

Is Miacalcin effective with osteoporosis?

"Miacalcin injection can help treat osteoporosis in postmenopausal women who are more than 5 years past menopause. The evidence that it works comes from trials where people taking the injection had increases in the amount of calcium in their bodies. However, it has not been shown to help reduce fractures."

Answered by AI

What kind of drug is Miacalcin?

"Calcitonin is a medication that comes in the form of a nasal spray or injection. It is used to treat osteoporosis in postmenopausal females, Paget's disease of bone, and high calcium. Although it is available in a generic form, it is not typically the first choice for treatment."

Answered by AI

What is Miacalcin used for?

"This medication is used to treat certain bone problems, such as Paget's disease, postmenopausal osteoporosis, by reducing high blood levels of calcium. Calcitonin, a man-made hormone, works by slowing bone loss and maintaining normal calcium levels in the blood."

Answered by AI

Clinical Trials for Miacalcin

Image of Don tyson Center for Agricultural Sciencers in Fayetteville, United States.

Protein and Exercise for Postmenopausal Women

Any Age
Female
Fayetteville, AR
The goal of this clinical trial is to learn if consuming a higher protein diet that includes one serving of beef each day, in combination with resistance exercise, improves wellbeing in postmenopausal women. It will also tell us about how higher protein intake changes body composition and blood values related to health. The main questions it aims to answer are: * Does higher protein intake combined with resistance training improve mood and sleep in postmenopausal women? * What other health benefits to postmenopausal women experience when the follow a higher protein diet and participate in resistance exercise? Researchers will compare three groups 1) postmenopausal women living their daily lives as usual, 2) postmenopausal women consuming a higher protein diet, and 2) postmenopausal women consuming a higher protein diet and participating in resistance training. Participants will: * Consume a higher protein diet for 16 weeks * Participate in an at-home resistance training for 16 weeks * Keep a diary of their food intake, sleep habits, and mood * Have health assessments every 4 weeks
Recruiting
Has No Placebo
Don tyson Center for Agricultural Sciencers (+1 Sites)Jamie Baum
Have you considered Miacalcin clinical trials? We made a collection of clinical trials featuring Miacalcin, we think they might fit your search criteria.Go to Trials
Image of University of Maryland, Baltimore, Department of Epidemiology and Public Health, Division of Gerontology in Baltimore, United States.

OPTIONS Program for Osteoporosis

65+
All Sexes
Baltimore, MD
Osteoporosis is a disease that weakens bones so the bones may break easily. The risk for osteoporosis increases with age in both women and men. Osteoporosis affects 10 million older adults in the US. Osteoporosis is a common cause of broken bones in the hips and legs. Broken bones can lead to disability, nursing home placement, and death. Because of the dire consequences, a broken hip or leg is one of the most dreaded injuries for older adults. Many studies confirm that a simple regimen of exercise, healthy diet and bone-strengthening medications can improve overall recovery after a broken hip or leg. This regimen can prevent a person from becoming disabled, having future fractures, and even prevent death. Many older adults have surgery in a hospital after breaking a hip or leg. Then older adults go to a skilled nursing facility (SNF) for rehabilitation. Care in SNFs varies greatly. Some patients do not receive the regimen that the investigators know is most beneficial to improve bone health and recovery. Even patients who get exercise, healthy diet, and bone-strengthening medication in the SNF, may not continue with the regimen once patients go home. Therefore, the investigators want to implement and test OsteoPorotic fracTure preventION System (OPTIONS). OPTIONS is a program that will integrate the regimen into the care that is provided in SNFs and after discharge to the community. OPTONS will provide information about exercise, diet, and bone-strengthening medication. OPTIONS will provide doctors, clinical staff, patients, and care partners with the information these stakeholders need to carry out the best-practice regimen. The investigators are partnering with PointClickCare, a large cloud-based healthcare software provider, with SNFs and community care sites across the US. The investigators will include 32 SNFs from different US areas. The investigators will flip a coin to assign SNFs to the intervention (OPTIONS) or the control arm (enhanced usual care) of the study. Enhanced usual care is the care that is typically provided in SNFs after a fracture and adding information about a publicly available fall prevention toolkit. The investigators are using an "implementation science" approach that requires the investigators to get input from the OPTIONS study's vast stakeholder community throughout the study. The OPTIONS study's stakeholders include patients, care partners, clinicians, and professional organizations. The research question is, can using OPTIONS in SNFs and in the community after discharge improve physical function and quality of life in older people in the year after a hip or leg fracture? The investigators are measuring patient-reported outcomes. The investigators will include 1553 patients across the 32 facilities. The investigators have selected outcomes that are important to patients. Specifically, the investigators are measuring patient-reported function and quality of life. The investigators are also measuring patient-reported falls and fractures. The investigators will track the number of patients who die during the study. This study's hypothesis is that patients who receive OPTIONS will report better physical function (i.e., can walk and take better care of themselves) than those who receive enhanced usual care. The investigators also hypothesize that patients that receive OPTIONS will report a better quality of life than those who receive enhanced usual care. This study will provide sound data about the effectiveness of OPTIONS. OPTIONS could then be spread to other SNFs and community-based programs. This would ensure that all older people receive the right care after a hip or leg fracture.
Waitlist Available
Has No Placebo
University of Maryland, Baltimore, Department of Epidemiology and Public Health, Division of Gerontology (+1 Sites)Denise Orwig, PhD
Image of Arthritis Research Canada in Vancouver, Canada.

Virtual Rehabilitation for Spinal Fracture

18+
All Sexes
Vancouver, Canada
Spine fractures are the most common fracture due to osteoporosis. They happen during falls or activities of daily life, like bending to tie shoes. Fractures of the spine can result in pain, which can sometimes last for a long time. Spine fractures can affect breathing, appetite, digestion, and mobility, and can restrict or modify people's work or daily activities. There are no standard rehabilitation programs after spine fracture, and patients often have to pay for rehabilitation. Rehabilitation can be hard to access, especially in rural or remote locations. It can be hard to find health care or rehabilitation providers who specialize in treating spine fractures. After reviewing research and consulting patients and health care providers to understand their experiences with spine fracture rehabilitation, the research team developed a toolkit for a virtual rehabilitation program for people with spine fractures, called VIVA. The research team wants to submit a grant for a clinical trial to implement VIVA in five provinces and determine if VIVA reduces pain and improves physical functioning and quality of life, and if the benefits outweigh the costs. Before this, the team proposes to do a pilot study to test how feasible it is to do a study of VIVA in three provinces.
Recruiting
Has No Placebo
Arthritis Research Canada (+5 Sites)Lora Giangregorio, PhD
Have you considered Miacalcin clinical trials? We made a collection of clinical trials featuring Miacalcin, we think they might fit your search criteria.Go to Trials
Image of Marcus Institute for Aging Research, Hebrew SeniorLife in Boston, United States.

Injury Prevention Care Models for Osteoporosis

65+
All Sexes
Boston, MA
The goal of this clinical trial is to compare three care models for optimizing medications and preventing falls with broken bones in patients receiving rehabilitation after a hospitalization for a broken bone. The primary outcome is injurious falls, with secondary outcomes measuring how the process of care is changed and capturing patient-reported outcomes valued by stakeholders. The main questions this study aims to answer are: * Which of the three models is more effective in preventing falls with fractures? * What are the differences in patient-centered outcomes amongst the three models? These include pain, depression, anxiety, sleep, medication side effect burden, and fear of falling. * What are the differences in osteoporosis treatment and medication burden? The three care models are: a Deprescribing Care Model designed to reduce or stop fall-related medications, a Bone Heath Service Model designed to provide osteoporosis evaluation and management, and an Injury Prevention Service Model offering both services. 42 SNFs will participate in this study. The three models will be incorporated into the routine care of patients at these facilities who are receiving rehabilitation after a hospitalization for a fracture. All care models will be delivered remotely to patients in the SNF and after they transition home by a post-fracture nurse consultant supported by an interprofessional team. This study has three aims. See Detailed Description for more details. This ClinicalTrials.gov record represents the Comparative Effectiveness Aim of the protocol.
Waitlist Available
Has No Placebo
Marcus Institute for Aging Research, Hebrew SeniorLife (+1 Sites)Cathleen S Colon-Emeric, MD, MHS
Image of University of Saskatchewan in Saskatoon, Canada.

Milk + Yogurt for Bone Health

19 - 30
All Sexes
Saskatoon, Canada
Milk and dairy products contain significant amounts of nutrients that contribute to optimal health - nutrients like calcium, vitamin D, and high-quality protein. Fermented milk products or fermented dairy products are dairy foods that have been fermented with certain bacteria. Yogurt is a fermented dairy product containing millions of beneficial bacteria. In this study, the invesgitagtors will look at the effect of milk (a non-fermented dairy product) and yogurt (a fermented dairy product) supplementation on bone health and the amount of fat and muscle mass in Canadian young adults over a 24-month period. While dairy products contain significant amounts of nutrients, the scientific community does not know the impact of long-term supplementation of fermented (i.e., yogurt) or non-fermented (i.e., milk) dairy food on bone health and the amount of fat and muscle mass in young adults. To fill this knowledge gap, the investigators will recruit participants with low calcium intake and assign them to three different groups: 1) milk (intervention) group; 2) yogurt (intervention) group; and 3) control group. The investigators will ask the participants in the milk group to drink 1.5 servings (375 mL) of milk per day for 24 months. Participants in the yogurt group will consume 2 servings (350 g) of yogurt per day for 24 months. Those in the control group will continue their usual diets. Using a randomized controlled trial design, the investigators will measure bone health parameters, hormonal indices related to bone metabolism, body composition (e.g., muscle mass, fat mass), and the number and composition of bacteria living in the gastrointestinal (GI) tract. The hypothesis is that supplementation with yogurt will have more positive effects on bone health indices, particularly femoral neck BMD as the primary outcome, than milk in Canadian adults aged 19-30 years. The secondary hypothesis is that supplementation with yogurt, as a fermented milk product, will have a more beneficial effect than milk on body composition measures. The data will provide valuable information for developing targeted health initiatives and marketing strategies regarding the benefits of fermented and non-fermented dairy product consumption.
Recruiting
Has No Placebo
University of SaskatchewanHassan Vatanparast, MD, PhD
Image of University of Kentucky in Lexington, United States.

Teriparatide vs Alendronate for Osteoporosis

18+
Female
Lexington, KY
Osteoporosis is a health problem of major proportions. It affects more than 40 million Americans and results in more than 2 million fractures annually among Medicare patients alone. Hospital admissions for osteoporotic fractures exceed those of heart attacks, strokes and breast cancer combined. Osteoporosis is commonly considered a disease associated with menopause. This estrogen deficiency related bone loss is characterized by high bone turnover with increased resorption without commensurate changes in bone formation. It is in contrast to age-related bone loss, which starts as early as in the fourth decade of life and continues with increasing age. Age-related bone loss is usually associated with lower bone turnover and decreased bone formation is the main abnormality. Current therapies do not address age-related bone loss and the special needs of the age-related osteoporosis population is currently ignored. This is to a great degree due to difficulties associated with the bone biopsy necessary for unequivocal determination of bone turnover status. Thus, the current standard of care relies on starting with an antiresorber, which is of limited effectiveness in age-related osteoporosis, and in fact impedes the effectiveness of the appropriate anabolic medication. In a current ongoing study - Novel precision medicine approach to treatment of osteoporosis based on bone turnover. EIRB#70781; efforts are focused on addressing this particular problem. Our follow-up study seeks to achieve one specific aim: to compare effectiveness of Alendronate vs Teriparatide after participants have been switched at the end of treatment at year one, to the other drug at year two for the same duration of treatment.
Phase 4
Waitlist Available
University of KentuckyPaul Netzel, DNP
Have you considered Miacalcin clinical trials? We made a collection of clinical trials featuring Miacalcin, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security